Peter J.  Wilkinson net worth and biography

Peter Wilkinson Biography and Net Worth

Senior Vice President and Chief Accounting Officer

What is Peter J. Wilkinson's net worth?

The estimated net worth of Peter J. Wilkinson is at least $475,502.08 as of April 29th, 2024. Mr. Wilkinson owns 2,087 shares of Laboratory Co. of America stock worth more than $475,502 as of December 23rd. This net worth estimate does not reflect any other investments that Mr. Wilkinson may own. Learn More about Peter J. Wilkinson's net worth.

How old is Peter J. Wilkinson?

Mr. Wilkinson is currently 53 years old. There are 7 older executives and no younger executives at Laboratory Co. of America. The oldest executive at Laboratory Co. of America is Ms. Sandra D. van der Vaart J.D., Executive VP, Chief Legal Officer & Corporate Secretary, who is 64 years old. Learn More on Peter J. Wilkinson's age.

How do I contact Peter J. Wilkinson?

The corporate mailing address for Mr. Wilkinson and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Peter J. Wilkinson's contact information.

Has Peter J. Wilkinson been buying or selling shares of Laboratory Co. of America?

Peter J. Wilkinson has not been actively trading shares of Laboratory Co. of America in the last ninety days. Most recently, Peter J. Wilkinson sold 2,439 shares of the business's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $204.33, for a transaction totalling $498,360.87. Following the completion of the sale, the chief accounting officer now directly owns 2,087 shares of the company's stock, valued at $426,436.71. Learn More on Peter J. Wilkinson's trading history.

Who are Laboratory Co. of America's active insiders?

Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Lance Berberian (EVP), Brian Caveney (EVP), Jonathan DiVincenzo (EVP and President, Central Laboratories and International), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.

Are insiders buying or selling shares of Laboratory Co. of America?

During the last year, insiders at the medical research company sold shares 23 times. They sold a total of 113,495 shares worth more than $25,408,653.12. The most recent insider tranaction occured on December, 2nd when EVP Glenn A Eisenberg sold 11,711 shares worth more than $2,815,675.73. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.

Information on this page was last updated on 12/2/2024.

Peter J. Wilkinson Insider Trading History at Laboratory Co. of America

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/29/2024Sell2,439$204.33$498,360.872,087View SEC Filing Icon  
11/16/2023Sell1,384$210.71$291,622.642,087View SEC Filing Icon  
8/1/2022Sell2,576$258.40$665,638.401,887View SEC Filing Icon  
2/18/2021Sell2,317$241.51$559,578.67710View SEC Filing Icon  
2/21/2020Sell297$189.65$56,326.05297View SEC Filing Icon  
See Full Table

Peter J. Wilkinson Buying and Selling Activity at Laboratory Co. of America

This chart shows Peter J Wilkinson's buying and selling at Laboratory Co. of America by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Laboratory Co. of America Company Overview

Laboratory Co. of America logo
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
Read More

Today's Range

Now: $227.84
Low: $225.25
High: $228.59

50 Day Range

MA: $232.13
Low: $214.13
High: $246.22

2 Week Range

Now: $227.84
Low: $191.97
High: $247.99

Volume

510,368 shs

Average Volume

658,998 shs

Market Capitalization

$19.06 billion

P/E Ratio

44.07

Dividend Yield

1.26%

Beta

1.05